Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan

Background It was reported that eribulin regulates the tumor microenvironment, including the immune system, by inducing vascular remodeling. Lymphocyte counts are a critical index of immune response in patients. The non-Asian, global EMBRACE study has suggested that baseline absolute lymphocyte coun...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer (Tokyo, Japan) Japan), 2021-07, Vol.28 (4), p.945-955
Main Authors: Takahashi, Masato, Inoue, Kenichi, Mukai, Hirofumi, Yamanaka, Takashi, Egawa, Chiyomi, Miyoshi, Yasuo, Sakata, Yukinori, Muramoto, Kenzo, Ikezawa, Hiroki, Matsuoka, Toshiyuki, Tsurutani, Junji
Format: Article
Language:English
Subjects:
Administration, Intravenous
Adult
Aged
Analysis
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - drug therapy
Breast Neoplasms - mortality
Cancer patients
Cancer Research
Eribulin mesylate
Female
Follow-Up Studies
Furans - administration & dosage
Humans
Immune response
Japan - epidemiology
Ketones - administration & dosage
Lymphocyte Count
Lymphocytes
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Middle Aged
Neutrophils
Oncology
Original
Original Article
Patient outcomes
Proportional Hazards Models
Receptor, ErbB-2
Surgery
Surgical Oncology
Tubulin Modulators - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background It was reported that eribulin regulates the tumor microenvironment, including the immune system, by inducing vascular remodeling. Lymphocyte counts are a critical index of immune response in patients. The non-Asian, global EMBRACE study has suggested that baseline absolute lymphocyte count (ALC) may be a predictor of the survival benefit of eribulin in breast cancer patients. We examined whether the baseline ALC is a potential predictor of overall survival (OS) in Japanese patients with HER2-negative advanced breast cancer treated with eribulin. Methods This was a post hoc analysis of data from a post-marketing observational study of eribulin in Japan. The OS by baseline ALC was estimated using the Kaplan–Meier method, with the cut-off value of 1500/μL for ALC. The OS by baseline neutrophil-to-lymphocyte ratio (NLR), a general prognostic index in breast cancer patients, was also estimated, with the cut-off value of 3. Results The median OS was longer in patients with an ALC of ≥ 1500/μL than in those with an ALC of 
ISSN:1340-6868
1880-4233
DOI:10.1007/s12282-021-01232-1